Sector consensus Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq Other stock markets 06:00:00 13/06/26 am AEST			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

12/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
12/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Average Target P.	Objective/dr gap	Nbr of analysts
ARGENX SE			846.68	+8.05%	15
WUXI APPTEC CO., LTD.			145.96	+46.39%	16
BIONTECH SE			106.48	+36.71%	19
INSMED INCORPORATED			197.62	+101.96%	21
WUXI BIOLOGICS (CAYMAN) INC.			40.49	+50.93%	22
EXELIXIS, INC.			49	-7.77%	16
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.			547.64	+31.9%	17
PHARMAESSENTIA CORPORATION			810.5	-14.59%	6
MADRIGAL PHARMACEUTICALS, INC.			678.71	+41.17%	14
ARROWHEAD PHARMACEUTICALS, INC.			88.17	+18.31%	12
AKESO, INC.			148.86	+87.12%	20
SUMMIT THERAPEUTICS INC.			21.28	+103.44%	13
NUVALENT, INC.			128.12	+3.96%	16
CYTOKINETICS, INCORPORATED			104.7	+49.25%	20
IMMUNITYBIO, INC.			13	+83.1%	3
REMEGEN CO., LTD.			99.09	+53.91%	14
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	770,000	+72.45%	1
BIOCON LIMITED			414.05	-1.18%	20
Average			43,024.46	+42.51%	15
Weighted average by Cap.			19,740.91	+38.79%	16